Number of pages: 100 | Report Format: PDF | Published date: 17 January, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Market size value in 2021 |
US$ 1.65 billion |
Revenue forecast in 2030 |
US$ 6.08 billion |
Growth Rate |
CAGR of 15.6% from 2022 to 2030 |
Base year for estimation |
2021 |
Forecast period |
2022-2030 |
Segments covered |
components, materials, application, end-user, and region. |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global 3D Bioprinting market was valued at US$ 1.65 billion in 2021 and is expected to register a revenue CAGR of 15.6% to reach US$ 6.08 billion by 2030.
Market Fundamentals
3D bioprinting is a type of additive manufacturing that uses cells and biomaterials to generate 3-dimensional (3D) constructions that operate as tissues. These biomaterials are further referred to as bio-inks, which are used to replicate biological tissues. Bioprinting has shown massive potential in the past decade and has a wide range of applications in areas such as regenerative medicine, drug discovery and development, and 3D cell culture.
[2574524]
Market Dynamics
The global 3D bioprinting market has illustrated significant revenue growth in recent years and is expecting a continued trend. The revenue growth of this market can be attributed to various factors such as the growing need for organ transplantation and care and large unmet needs in regenerative medicine and drug discovery and development. The growing influence of 3D bioprinting with its key role in healthcare facilities, especially in drug testing and tissue engineering, further adds to market revenue growth. 3D bioprinting is frequently used in the development of regenerative technologies and personalized medications as it produces highly tailored tissue models that outperform traditional tissue engineering approaches. The model can replicate actual tissue and be created in a high-throughput way using microarrays. These 3D tissue models can help in analyzing the efficacy of potential treatments, improving their uptake and, as a result, contributing to market revenue growth. Additionally, rapidly growing research activities in 3D tissue modeling and advancement in technologies and materials also encourage overall market revenue growth. Furthermore, increasing private and public investment/funding for R&D initiatives supports market revenue growth. Conversely, the dearth of specialized professionals and the high cost of 3D bioprinting processes are some factors that can restrain the market revenue growth.
Market Ecosystem
The global 3D bioprinting market is analyzed from five perspectives: components, materials, application, end-user, and region.
3D Bioprinting Market by Components
[2455646]
Based on components, the global 3D bioprinting market is segmented into 3D bioprinters and bio-inks.
The 3D bioprinters segment dominates the market with the largest revenue share. The 3D bioprinters segment is further segmented into inkjet, laser, magnetic, and micro-extrusion/syringe bioprinters. Inkjet 3D bioprinters lead the segment with the largest revenue share. 3D bioprinters assist in building up the materials to construct 3D tissue using the layer-by-layer methodology, while the development of this structure can be assisted by various types of bioprinters. The inkjet printer provides a high resolution and high cell viability. Additionally, inkjet bioprinters come with advantages such as good speed, large availability, and affordability. Thus, these factors encourage the revenue growth of this segment. However, unreliable cell encapsulation or problems related to the droplet directions are some of the drawbacks of inkjet bioprinters.
On the other hand, the bio-inks segment is also expected to register significant revenue growth during the projected timeline.
3D Bioprinting Market by Materials
Based on the materials, the global 3D bioprinting market is segmented into hydrogel, cell, extracellular matrices, and biomaterials.
Hydrogel, also known as collagen, accounts for the largest revenue share in the market. The revenue growth of this segment can be attributed to its wide utilization in the development of bone, skin, tendons, and various other soft tissues. Hydrogel assists in forming fibrous networking, and has high biodegradability, and biocompatibility.
3D Bioprinting Market by Application
Based on the application, the global 3D bioprinting market is segmented into pharmaceuticals, organ & tissue regeneration, 3D cell culture, and others.
The pharmaceuticals segment accounts for the largest revenue share in the global market. The revenue growth of this segment can be attributed to the increasing demand for novel drugs due to the rise in the prevalence of chronic diseases. Furthermore, the growing popularity and adoption of personalized drugs contribute to the revenue growth of this segment.
3D Bioprinting Market by End-user
Based on the end-user, the global 3D bioprinting market is segmented into research centers & academics, biopharmaceutical, and others.
The biopharmaceutical segment leads the market with the largest revenue share. The revenue growth of this segment can be attributed to the increasing need for enhanced drugs & therapies (especially in oncology) and also rising tissue modeling and miniature cellular models, thus encouraging the revenue growth of this segment.
3D Bioprinting Market by Region
Based on region, the global 3D bioprinting market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominates the market due to its largest revenue share. The revenue growth of this region can be attributed to the high prevalence of chronic diseases and a high percentage of transplantation procedures. For instance, around 110,000 people in the United States are on the waiting list for an organ transplant, and nearly 20-25 patients die every day owing to a lack of organ transplantation stated the Health Resources and Services Administration (HRSA). Additionally, the presence of major market players with growth initiatives in this region further fuels the market revenue growth in North America.
Competitive Landscape
The prominent players operating in the global 3D bioprinting market are:
Strategic Developments
In June 2022, Brinter, a Finnish bioprinting company developed the world's first multi-material, multi-fluidic bioprinting printhead. With the launch of this advanced technology, the company focuses on expanding its bioprinter device sales in the US and Europe markets.
Global 3D bioprinting is expected to reach US$ 6.08 billion by 2030.
Global 3D bioprinting is expected to register a revenue CAGR of 15.6% during the forecast period from 2022 to 2030.
The bioprinters segment accounts for the largest revenue share of the global 3D bioprinting market.
The lack of skilled and experienced professionals and the high cost of 3D bioprinting are some of the restraints in the 3D bioprinting market.
The biopharmaceutical segment dominates the 3D bioprinting industry.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.